SARS-CoV-2 3CLpro-IN-35

Overview

SARS-CoV-2 3CLpro-IN-35 is a SARS-CoV-2 3CLpro inhibitor with an IC 50 of 0.15 μM. SARS-CoV-2 3CLpro-IN-35 inhibits the proliferation of bladder cancer cells, exerts anti-SARS-CoV-2 activity, and exhibits low cytotoxicity in fibroblasts. SARS-CoV-2 3CLpro-IN-35 is applicable to research related to SARS-CoV-2 infection and bladder cancer .

Application

Products | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Bladder Cancer | Products > Disease Areas > Urogenital Cancer | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > SARS-CoV

Product Information

• Catalog No.: HY-181489
• CAS No.: 3023042-32-9
• Molecular Formula: C32H24F6O6
• Molecular Weight: 618.52
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source